Fragile X Syndrome Screen
With over 99% accuracy, the NxGen MDx screen for fragile X syndrome is one of the world’s most accurate tests for detecting genetic markers that may affect pregnancy and future child development.
What Is It?
Fragile X syndrome affects approximately 1 in 4,000 males and 1 in 8,000 females. The majority of males with fragile X syndrome have a significant intellectual disability. The spectrum ranges from learning disabilities to severe mental retardation and autism. About one third of the females affected with fragile X syndrome have a significant intellectual disability. Others may have more moderate or mild learning difficulties. To learn more about fragile X syndrome, view or download the Fact Sheet.
Who Should Take It?
• All individuals of child bearing age, regardless of gender
• All individuals with a family history of genetic disorders
• All individuals with partners who are carriers of a genetic disorder
• Couples or individuals considering in vitro fertilization
• Pregnant women
When testing, our laboratory analyzes all of the coding DNA in a gene to determine if any disease-causing pathogenic variants are present. By sequencing all of the coding DNA in a gene, instead of just a portion, we are able to offer the most accurate genetic testing available, regardless of your ethnicity. The majority of laboratories are only sequencing a portion of the gene, leaving room for error with missed pathogenic variants, especially when testing a variety of ethnicities. By sequencing the entire gene, NxGen MDx testing eliminates the doubt in a negative result and drastically reduces the residual risk, regardless of ethnicity.
- Chen et al. (2010). An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for Southern blot analysis. J Mol Diagn, 12:589-600.
- Cornish et al. (2004). Annotation: Deconstructing the attention deficit in fragile X syndrome: a developmental neuropsychological approach. J Child Psychol Psychiatry, 45(6):1042-1053.
- Cronister et al. (2008). Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet Gynecol, 111:596-601.
- Eichler et al. (1994). Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet, 8:88-94.
- Fernandez-Carvajal et al. (2009). Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn, 11:306-1310.
- Hagerman et al. (2002). Fragile X syndrome : Diagnosis, treatment, and research; 3rd ed.; Baltimore : Johns Hopkins University Press.
- Hagerman and Hagerman (2004). The fragile-X premutation: a maturing perspective. Am J Hum Genet, 74(5):805-16. Epub 2004 Mar 29. Review. Erratum in: Am J Hum Genet. 2004 Aug;75(2):352.
- Hagerman (2006). Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. J Dev Behav Pediatr, 27(1):63-74.
- Hantash et al. (2011). FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med, 13:39-45.
- Jacquemont et al. (2007). Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol, 6(1):45-55.
- Koukoui and Chaudhuri (2007). Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome. Brain Res Rev, 53(1):27-38.
- Nolin et al. (2003). Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. J Hum Genet, 2003, 72:454-464.
- Sherman et al. (2005). Fragile X syndrome: diagnostic and carrier testing. Genet Med, 7(8):584-587.
- Strom et al. (2007). Molecular testing for Fragile X Syndrome: lessons learned from 119,232 tests performed in a clinical laboratory. Genet Med, 9:46-51.
- Terracciano et al. (2005). Fragile X syndrome. Am J Med Genet C Semin Med Genet, 15;137(1):32-37.
- Van Esch (2006). The Fragile X premutation: new insights and clinical consequences. Eur J Med Genet, 49(1):1-8.
- Willemsen et al. (2004). The fragile X syndrome: from molecular genetics to neurobiology. Ment Retard Dev Disabil Res Rev, 10(1):60-67.
Talk to a Genetic Counselor
As a NxGen client, you'll have access to personal genetic counselors who can help explain the results of your screens and provide insight on how to move forward. To schedule a personal conference to discuss your screen results, call (855) 776-9436. or click the link below.Discuss Your Screening Results